/ Erasmus MC / SCLC /
MK-7684A
Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer.
Stadium
IV
Mutation
n/a
Lijn
1e lijn
Population
Patients with extensive Non-small Cell Lung Cancer
Design
Key outcome parameters
Intervention
MK-7684A, etoposide, atezolizumab, chemotherapy
Key inclusion criteria
Inclusion criteria:
- First line therapy
- Stage IV
- ECOG 0-1
Key exclusion criteria
Exclusion criteria:
- Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, or severe or life-threatening superior vena cava syndrome
- Has received prior treatment (systemic therapy including investigational agents, curativeintent radiotherapy, or curative-intent surgical resection) for SCLC
- Has known active CNS metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in past 2 years
